Peptide Therapy Cost in 2026: A Complete Pricing Breakdown by Peptide Type

The Real Cost of Peptide Therapy: Why It Ranges from $100 to $1,500 Per Month

If you have spent any time researching peptide therapy, you have probably noticed that pricing information is frustratingly inconsistent. One clinic quotes $150 per month for CJC-1295/Ipamorelin. Another quotes $600 for what appears to be the same treatment. A telemedicine platform advertises semaglutide for $299, while your local pharmacy wants $1,349 for a brand-name Wegovy prescription. The price of BPC-157 varies by a factor of five depending on where you look.

This is not a market in chaos — it is a market with genuinely complex pricing dynamics driven by regulatory status, patent protection, compounding versus brand-name sourcing, clinic overhead models, and geographic variation. Understanding these dynamics is essential if you want to get effective peptide therapy at a fair price without falling for either overpriced boutique clinics or dangerously cheap gray-market products.

This guide provides a comprehensive, category-by-category breakdown of peptide therapy costs as of April 2026. Every price range cited comes from our analysis of pricing data across 800+ clinics in the PeptideProbe directory, supplemented by wholesale pricing from major 503A and 503B compounding pharmacies. We update this data quarterly, so the figures you see here reflect the current market — not outdated estimates from 2024 or early 2025.

Why Peptide Therapy Prices Vary So Much

Before diving into specific peptide costs, it helps to understand the seven primary factors that drive pricing variation:

1. Brand-Name vs. Compounded

This is the single largest determinant of cost. Brand-name peptide drugs — Wegovy (semaglutide), Zepbound (tirzepatide), Egrifta (tesamorelin) — carry patent-protected pricing set by pharmaceutical manufacturers. These products have undergone full FDA clinical trials costing hundreds of millions of dollars, and the prices reflect that investment. A brand-name GLP-1 agonist can cost $800-$1,500 per month at retail, whereas the same active molecule compounded by a 503A or 503B pharmacy might cost $150-$400.

The legality of compounding FDA-approved molecules is nuanced and evolving. In general, compounding pharmacies can produce copies of FDA-approved drugs when there is a documented shortage (which has been the case for semaglutide and tirzepatide for much of 2024-2026) or when the prescriber documents a need for a specific customization (different concentration, removal of an allergen, combination with another drug). As shortages resolve, the legality of compounded versions may change — a critical factor we discuss in more detail below.

2. The Pharmacy: 503A vs. 503B

Compounding pharmacies come in two regulatory categories. 503A pharmacies compound medications based on individual patient prescriptions. They are regulated primarily at the state level, with FDA oversight limited to general enforcement. 503B pharmacies (also called outsourcing facilities) can compound larger batches without individual prescriptions and are subject to more rigorous FDA oversight, including current Good Manufacturing Practice (cGMP) requirements and regular FDA inspections.

503B pharmacies generally charge more than 503A pharmacies due to their higher regulatory compliance costs, but they offer greater assurance of product quality, potency, and sterility. For injectable peptides — where sterility is non-negotiable — many clinicians prefer to source from 503B facilities. The price premium is typically 20-40% over comparable 503A products, but the additional quality assurance is worth the cost in most patients' assessment.

3. Clinic Markup and Service Model

Some clinics dispense peptides directly (buy-and-bill model), purchasing from compounding pharmacies at wholesale and marking up 50-200% to cover their overhead and profit margin. Others write prescriptions that patients fill at their preferred pharmacy, charging only for the consultation and monitoring. The buy-and-bill model is convenient — everything is handled by the clinic — but it is almost always more expensive than obtaining the peptides independently through a compounding pharmacy.

Telemedicine platforms have introduced a third model: bundled subscription pricing where the consultation, lab monitoring, and medications are included in a single monthly fee. These platforms benefit from volume purchasing and low overhead, and they often offer the most competitive pricing — but the tradeoff is less personalized care and limited physical examination capabilities.

4. Dosing Protocol

The same peptide can vary dramatically in cost depending on the prescribed dose. Semaglutide at 0.25 mg weekly (the starting dose) costs roughly one-quarter the amount of semaglutide at 1.0 mg weekly (a common maintenance dose). CJC-1295/Ipamorelin at 100/100 mcg once daily is half the cost of 300/300 mcg twice daily. When comparing prices between clinics, always ensure you are comparing the same dose and frequency.

5. Geographic Location

Peptide therapy costs vary by region, reflecting differences in local cost of living, clinic density (more competition generally means lower prices), and state-level regulations. Clinics in New York City, San Francisco, and Miami tend to charge 30-60% more than comparable providers in mid-sized cities like Nashville, Denver, or Austin. Rural areas often have fewer options, which can paradoxically lead to either very high prices (due to lack of competition) or very low prices (if a single provider operates with low overhead).

6. Consultation and Monitoring Fees

The peptide medication itself is only part of the total cost. Most clinics charge separately for initial consultations ($100-$350), follow-up visits ($75-$200), and laboratory work ($100-$400 per panel). Some clinics bundle these costs into a monthly subscription; others bill each component separately. A clinic that appears cheaper on peptide pricing alone may be more expensive overall once consultation and lab fees are factored in.

7. Duration and Commitment

Many clinics offer volume discounts for longer commitments. A 3-month supply of CJC-1295/Ipamorelin might be 15-20% cheaper per month than a single-month supply. Some telemedicine platforms offer 6-month or annual plans with even steeper discounts. If you are confident in your protocol and plan to continue for several months, asking about multi-month pricing is one of the easiest ways to reduce costs.

GLP-1 Agonist Costs: Brand-Name vs. Compounded Pricing in 2026

GLP-1 receptor agonists (semaglutide and tirzepatide) are by far the most discussed peptides in terms of pricing, because the gap between brand-name and compounded pricing is enormous — and because ongoing FDA regulatory actions continue to shift the availability of compounded versions.

Brand-Name GLP-1 Pricing (April 2026)

Product	Manufacturer	List Price / Month	With Insurance (Avg Copay)	With Manufacturer Coupon
Wegovy (semaglutide)	Novo Nordisk	$1,349	$25-$150	$0-$500
Ozempic (semaglutide)	Novo Nordisk	$935	$25-$100	$0-$300
Rybelsus (oral semaglutide)	Novo Nordisk	$935	$25-$100	$0-$300
Zepbound (tirzepatide)	Eli Lilly	$1,059	$25-$150	$0-$550
Mounjaro (tirzepatide)	Eli Lilly	$1,023	$25-$100	$0-$500

Compounded GLP-1 Pricing (April 2026)

Compounded semaglutide remains available in 2026, though the regulatory landscape has tightened considerably since the FDA resolved the semaglutide shortage in late 2025. As of April 2026, 503B outsourcing facilities can continue compounding semaglutide under certain conditions related to ongoing demand and customization requirements. Several legal challenges are working through the courts, and the situation could change within months.

Compounded Product	Typical Monthly Cost	Pharmacy Type	Notes
Semaglutide (injectable)	$150-$450	503A / 503B	Regulatory status in flux; verify current legality
Semaglutide (sublingual)	$200-$500	503A / 503B	Newer formulation; bioavailability data limited
Tirzepatide (injectable)	$200-$500	503A / 503B	Less widely compounded than semaglutide

The savings from compounded GLP-1 agonists are substantial — typically 60-85% less than brand-name pricing. However, patients should be aware that compounded products do not undergo the same rigorous testing as FDA-approved products, and potency can vary between batches. Choosing a reputable 503B pharmacy with third-party testing certificates of analysis (COAs) is essential.

Growth Hormone Peptide Costs

Growth-hormone-releasing peptides are the bread and butter of peptide therapy clinics. They are less expensive than GLP-1 agonists, have been available through compounding pharmacies for over a decade, and have relatively stable pricing that has not been disrupted by the regulatory upheaval affecting some other peptide categories.

Peptide	Monthly Cost (Medication Only)	Typical Dose	Notes
CJC-1295 / Ipamorelin	$150-$400	100-300 mcg each, 1-2x daily	Most commonly prescribed GH peptide combo
Sermorelin	$120-$300	200-500 mcg daily	Lower cost, milder effects; great for beginners
Tesamorelin (compounded)	$200-$500	1-2 mg daily	Brand-name Egrifta costs $1,000-$1,500/mo
MK-677 (Ibutamoren)	$80-$200	10-25 mg daily (oral)	Cheapest GH-boosting option; oral dosing
GHRP-2	$100-$250	100-300 mcg, 2-3x daily	Increases appetite and cortisol more than Ipamorelin
GHRP-6	$80-$200	100-300 mcg, 2-3x daily	Oldest GHRP; significant appetite stimulation

Total Monthly Cost Including Clinic Fees

When you factor in consultation and monitoring fees, the total monthly cost of a GH peptide protocol typically looks like this:

• Telemedicine platform (all-inclusive): $200-$500/month for CJC-1295/Ipamorelin including medication, consultations, and basic lab reviews
• Brick-and-mortar clinic (buy-and-bill): $300-$700/month including medication markup, in-person consultations ($100-$200 per visit, typically monthly at first then quarterly), and lab monitoring
• Independent prescriber + separate pharmacy: $200-$450/month total — consultation fees ($75-$150 per visit) plus pharmacy costs ($120-$300 for medication)

Healing and Recovery Peptide Costs

Recovery peptides like BPC-157 and TB-500 tend to be less expensive than GH peptides and are often used for shorter durations (6-12 weeks rather than ongoing), which further reduces the total cost of treatment.

Peptide	Monthly Cost	Typical Duration	Total Treatment Cost
BPC-157 (injectable)	$100-$250	4-12 weeks	$100-$750
BPC-157 (oral capsules)	$80-$200	4-12 weeks	$80-$600
TB-500	$150-$350	6-12 weeks	$225-$1,050
BPC-157 + TB-500 combo	$200-$450	6-12 weeks	$300-$1,350
Pentosan Polysulfate (Zilosul)	$150-$300	8-16 weeks	$300-$1,200

Note that BPC-157's regulatory status changed in 2025 when it was among the peptides reclassified by the FDA. As of April 2026, BPC-157 remains available through certain compounding pharmacies, but availability is more restricted than it was in 2024. Patients should verify current availability with their prescriber and pharmacy before beginning a protocol.

Insurance Coverage for Peptide Therapy in 2026

Historically, insurance coverage for peptide therapy has been extremely limited. Most peptides prescribed by anti-aging and wellness clinics are used off-label, compounded, or both — and insurance companies have little incentive to cover treatments that lack FDA approval for the prescribed indication. However, 2026 has brought meaningful changes to this landscape, primarily driven by the GLP-1 revolution and Medicare's new anti-obesity drug program.

The 2026 Medicare GLP-1 Coverage Program

In March 2026, the Centers for Medicare & Medicaid Services (CMS) finalized a rule expanding Medicare Part D coverage to include GLP-1 receptor agonists for the treatment of obesity — a landmark policy change that had been debated for years. Previously, Medicare explicitly excluded coverage of drugs prescribed for weight loss. Under the new rule, Medicare beneficiaries with a BMI of 30 or higher (or 27+ with at least one weight-related comorbidity) can access brand-name semaglutide (Wegovy) and tirzepatide (Zepbound) with standard Part D cost-sharing.

The practical impact is significant: approximately 7.4 million Medicare beneficiaries are newly eligible for GLP-1 coverage, with estimated out-of-pocket costs of $35-$100 per month under most Part D plans — a fraction of the $1,000+ retail price. The program has also pressured private insurers to expand their own GLP-1 coverage. As of April 2026, an estimated 65% of commercial insurance plans now cover at least one GLP-1 agonist for obesity (up from approximately 40% in early 2025).

What Insurance Typically Covers

• FDA-approved peptides used for FDA-approved indications: Generally covered. Examples include semaglutide for type 2 diabetes (Ozempic) or obesity (Wegovy), tirzepatide for diabetes (Mounjaro) or obesity (Zepbound), and tesamorelin for HIV-associated lipodystrophy (Egrifta).
• FDA-approved peptides used off-label: Sometimes covered with prior authorization and documented clinical rationale. Coverage varies widely by plan. For example, some plans will cover tesamorelin for non-HIV visceral adiposity if the prescriber documents metabolic syndrome and failed lifestyle interventions.
• Compounded peptides: Rarely covered by insurance. Most plans explicitly exclude compounded medications, with occasional exceptions for compounded thyroid hormones and hormone replacement therapy.
• Non-FDA-approved peptides (BPC-157, CJC-1295/Ipamorelin, TB-500, etc.): Not covered by any insurance plan.

HSA and FSA Eligibility

Peptide therapy prescribed by a licensed healthcare provider generally qualifies as an eligible expense under Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). This applies to both the medication costs and the associated consultation and laboratory fees. Using pre-tax HSA/FSA dollars effectively reduces the cost by your marginal tax rate — a savings of 22-37% for most patients. Keep all receipts and the prescriber's documentation of medical necessity in case of audit.

How to Reduce Peptide Therapy Costs Without Sacrificing Quality

Given that most peptide therapy costs are out-of-pocket, maximizing value is a practical concern for the majority of patients. Here are evidence-based strategies for reducing costs without compromising safety or efficacy:

1. Compare Multiple Providers and Pharmacies

This is the single most effective cost-reduction strategy. Our analysis of PeptideProbe directory data shows that the price for identical peptide protocols can vary by 200-400% between providers in the same metropolitan area. Use the PeptideProbe directory to compare pricing across clinics, and do not hesitate to call compounding pharmacies directly to ask about their pricing for specific peptides. Many patients find that the cheapest option is to see an independent prescriber for the consultation and fill the prescription at a competitively priced compounding pharmacy — rather than using a single clinic that handles both.

2. Ask About Multi-Month Pricing

Most compounding pharmacies and telemedicine platforms offer significant discounts for 3-month, 6-month, or annual commitments. Typical savings range from 10-25% compared to month-by-month pricing. If you are on a stable protocol that you plan to continue, this is essentially free money.

3. Consider Telemedicine Platforms

Telemedicine peptide therapy platforms have lower overhead than brick-and-mortar clinics and pass some of those savings to patients. Monthly all-inclusive pricing (consultation + medication + lab review) on major platforms typically runs 20-40% less than comparable in-person clinic packages. The tradeoff is less hands-on care and the inability to perform physical examinations, but for straightforward peptide protocols in otherwise healthy patients, telemedicine is a cost-effective option.

4. Optimize Your Protocol

Work with your prescriber to ensure you are on the minimum effective dose. More is not always better with peptides — particularly GH-releasing peptides, where studies show that moderate doses (e.g., CJC-1295/Ipamorelin 100/100 mcg daily) produce 70-80% of the IGF-1 elevation seen with higher doses (300/300 mcg daily) at a fraction of the cost. Starting low and titrating based on lab results is both medically prudent and cost-effective.

5. Use HSA/FSA Funds

As noted above, peptide therapy prescribed by a licensed provider is generally HSA/FSA-eligible. If you have access to these accounts, using pre-tax dollars effectively reduces your cost by 22-37% depending on your tax bracket. Max out your contributions if peptide therapy is a significant annual expense.

6. Leverage Manufacturer Savings Programs

For brand-name medications, manufacturer copay cards and patient assistance programs can dramatically reduce costs. Novo Nordisk offers savings programs for Wegovy and Ozempic that can reduce copays to $0-$25 per month for commercially insured patients. Eli Lilly has a similar program for Zepbound and Mounjaro. These programs change frequently, so check the manufacturer websites directly for current offers.

7. Time Your Lab Work Strategically

Laboratory monitoring is a necessary but sometimes overpriced component of peptide therapy. Many clinics mark up lab panels by 100-300% compared to direct-to-consumer lab services like Quest Diagnostics' QuestDirect or Labcorp's OnDemand. Ask your provider if they accept outside lab results, and if so, order your panels through a direct-to-consumer service. A comprehensive metabolic panel with IGF-1 and hormone levels that a clinic charges $400 for can often be obtained for $100-$150 through these services.

Red Flags for Overpriced Providers

While peptide therapy is not cheap, some providers charge unreasonable prices by exploiting patients' unfamiliarity with market rates. Watch for these warning signs:

Excessive Initial "Program" Fees

Some clinics charge $2,000-$5,000 upfront "program enrollment" or "comprehensive assessment" fees before any treatment begins. While a thorough initial consultation and lab panel ($200-$500 total) is reasonable, five-figure enrollment fees are a red flag. They are often justified with vague claims about "proprietary protocols" or "advanced testing panels" that do not meaningfully differ from standard peptide therapy workflows.

Proprietary "Blends" at Premium Prices

Be cautious of clinics that sell their own branded peptide "blends" or "formulas" at premium prices without disclosing the specific peptides and doses included. A legitimate clinic should be transparent about exactly what you are taking, at what dose, and from which pharmacy. "Proprietary" formulations are often standard peptides — like CJC-1295/Ipamorelin — repackaged with a custom label and a 300% markup.

Required Long-Term Contracts

Peptide therapy should be month-to-month or with voluntary multi-month discounts — not binding contracts. A provider that requires a 6-month or 12-month commitment with financial penalties for early termination is prioritizing their revenue over your clinical needs. Protocols should be adjustable based on your response, lab results, and changing goals.

Refusal to Share Pharmacy Information

You have a right to know which pharmacy compounds your medications. A clinic that refuses to disclose its pharmacy source, will not provide certificates of analysis, or becomes evasive when asked about product sourcing is a significant red flag. This opacity may indicate they are sourcing from unregulated or overseas suppliers — a safety concern that transcends pricing.

Prices Dramatically Below Market

While overpricing is the more common concern, dramatically low pricing can also be a red flag. If a provider offers semaglutide at $50 per month or CJC-1295/Ipamorelin at $40 per month, the product is likely sourced from an unregulated supplier, underdosed, or not what it claims to be. Gray-market peptides from overseas research chemical companies may cost a fraction of pharmacy-compounded products, but they carry genuine risks: bacterial contamination, incorrect dosing, degraded active ingredients, and the presence of unlisted compounds. The "savings" are not worth the risk.

A Realistic Monthly Budget by Goal

To help you plan, here is what a typical patient can expect to spend per month based on their primary treatment goal, including all associated costs (medication, consultations, and lab monitoring amortized monthly):

Treatment Goal	Recommended Protocol	Budget Range (Total Monthly)
Weight loss (GLP-1, brand-name with insurance)	Semaglutide or tirzepatide	$50-$200
Weight loss (GLP-1, compounded, cash pay)	Compounded semaglutide	$200-$550
Muscle growth / anti-aging	CJC-1295/Ipamorelin	$200-$500
Injury recovery	BPC-157 + TB-500	$250-$550
Comprehensive body recomposition	CJC-1295/Ipamorelin + low-dose GLP-1	$400-$900
Advanced muscle + recovery stack	CJC-1295/Ipamorelin + BPC-157 + TB-500	$450-$1,000
Sexual health (PT-141)	Bremelanotide (as needed)	$100-$300

Specialty Peptide Costs: Cognitive, Sexual Health, and Longevity

Beyond the major categories of GLP-1 agonists, growth hormone peptides, and healing peptides, a growing number of patients are seeking peptides for cognitive enhancement, sexual health, and longevity purposes. These specialty peptides occupy a smaller market niche but can represent a significant expense — particularly because insurance coverage is virtually nonexistent for these indications.

Cognitive and Neuroprotective Peptides

Peptides like Semax and Selank — developed in Russia and approved there for clinical use — have generated interest among patients seeking cognitive enhancement, stress reduction, and neuroprotection. However, the 2025-2026 FDA reclassification moved both of these peptides to Category 2, significantly restricting their availability through US compounding pharmacies. Before reclassification, Semax typically cost $100-$200 per month through compounding pharmacies, and Selank ran $120-$250 per month. Patients who were using these peptides have largely had to discontinue or seek alternatives.

Dihexa, another cognitive-enhancement peptide, was also reclassified to Category 2 due to concerns about its potent hepatocyte growth factor (HGF) mimetic activity and the absence of human safety data. Prior to reclassification, Dihexa cost $150-$350 per month. No direct replacement with comparable mechanism of action is currently available through legal compounding channels.

Sexual Health Peptides

PT-141 (bremelanotide) is the primary peptide used for sexual dysfunction. The FDA-approved version, Vyleesi, is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women and costs approximately $900-$1,000 per month at retail (roughly $100 per auto-injector, with 8 doses per box). Compounded PT-141 is significantly cheaper at $100-$300 per month and is commonly prescribed off-label for both men and women with various forms of sexual dysfunction.

Kisspeptin-10, an emerging peptide being studied for its effects on reproductive hormones and sexual arousal, is available through some compounding pharmacies at $150-$400 per month. Clinical data is limited but growing, and several Phase II trials are expected to report results in 2026-2027.

Longevity and Anti-Aging Peptides

The longevity peptide category has been significantly affected by the 2025-2026 reclassification, which moved Epitalon (a telomere-associated peptide) and several thymic peptides to Category 2. Before reclassification, a typical longevity-focused peptide protocol might include Epitalon ($200-$400/month), Thymosin Alpha 1 ($200-$500/month), and a growth hormone peptide like CJC-1295/Ipamorelin ($150-$400/month), bringing the total monthly cost for a comprehensive longevity stack to $550-$1,300 per month.

Post-reclassification, longevity protocols have shifted toward peptides that remain in Category 1 — primarily growth hormone peptides and NAD+ precursors (which are not peptides per se but are commonly offered by the same clinics). A typical 2026 longevity protocol might cost $200-$600 per month, a meaningful reduction from the pre-reclassification era but still a substantial ongoing expense.

Hidden Costs Patients Often Overlook

When budgeting for peptide therapy, patients frequently underestimate or entirely overlook several recurring costs that can add 20-40% to the total monthly expense:

Injection Supplies

If you are using compounded injectable peptides (as opposed to brand-name auto-injector pens), you will need to purchase injection supplies separately. These typically include insulin syringes ($10-$20 per box of 100), alcohol swabs ($5-$10 per box), bacteriostatic water for reconstitution ($10-$25 per vial), and sharps disposal containers ($5-$15 each). While individually inexpensive, these supplies add $15-$40 per month to your ongoing costs and are rarely included in quoted peptide prices.

Shipping and Handling

Many compounding pharmacies charge separately for cold-chain shipping — the insulated packaging and cold packs required to maintain peptide stability during transit. Cold-chain shipping fees typically range from $15-$35 per shipment. If you receive monthly shipments, this adds $180-$420 per year to your total cost. Some pharmacies include shipping in their pricing; others do not. Always ask whether the quoted price includes delivery.

Initial Consultation and Onboarding Costs

The first month of peptide therapy is almost always the most expensive due to one-time onboarding costs. These may include an initial consultation ($150-$350), comprehensive baseline laboratory panel ($200-$400), body composition testing such as a DEXA scan ($75-$200), and potentially an in-office injection training session ($50-$150). In total, first-month costs can exceed ongoing monthly costs by $400-$1,000, and patients should budget accordingly.

Periodic Lab Monitoring

While not a monthly expense, laboratory monitoring every 6-12 weeks adds significantly to the annualized cost of peptide therapy. A standard monitoring panel (comprehensive metabolic panel, IGF-1, fasting insulin, lipid panel, and sometimes thyroid and hormone levels) costs $100-$400 per draw depending on the provider and whether you use a direct-to-consumer lab service. Over the course of a year, lab costs can total $400-$1,600 — a figure that many patients fail to include in their initial budget calculations.

The Future of Peptide Therapy Pricing

Several trends suggest that peptide therapy costs will continue to evolve through 2026 and beyond:

• GLP-1 price compression: As more GLP-1 agonists enter the market (oral orforglipron, CagriSema, survodutide) and generic/biosimilar versions approach patent expiry timelines, competition will drive brand-name prices down. Some analysts predict a 30-50% reduction in GLP-1 costs by 2028.
• Regulatory tightening on compounding: The FDA's ongoing efforts to restrict compounding of drugs that are commercially available may reduce access to cheaper compounded versions of brand-name peptides. This could increase costs for patients who currently rely on compounding pharmacies.
• Insurance expansion: The Medicare GLP-1 coverage program is expected to create a domino effect, with more private insurers expanding coverage. This trend reduces out-of-pocket costs for insured patients but does not help cash-pay patients using non-FDA-approved peptides.
• Oral peptide development: As oral bioavailability improves for peptides currently limited to injection, manufacturing costs may decrease and patient convenience will increase — potentially reducing the total cost of therapy by eliminating the need for injection supplies and training.

Bottom Line: What You Should Expect to Pay

For most patients, effective peptide therapy costs between $200 and $600 per month when sourced through reputable compounding pharmacies and prescribed by qualified clinicians. Brand-name GLP-1 agonists are the major exception, costing $800-$1,500 without insurance but potentially as little as $25-$150 with coverage. The most important cost-saving strategies are comparing multiple providers, using HSA/FSA funds, asking about multi-month discounts, and ensuring you are on the minimum effective dose.

Use the PeptideProbe directory to compare pricing across peptide therapy clinics in your area. Our listings include transparent pricing information, patient reviews, and the specific peptides each clinic offers — so you can make an informed decision without surprise costs.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Pricing information is based on market analysis as of April 2026 and may vary by location, provider, and individual circumstances. Peptide therapies should only be obtained through licensed healthcare providers and regulated pharmacies. Insurance coverage varies by plan and is subject to change. Always verify current pricing and coverage with your provider and insurance company before beginning treatment.